Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison

Abstract

Aim To conduct an adjusted indirect treatment comparison (aITC) of the efficacy of tirzepatide 5/10/15 mg versus semaglutide 2 mg in patients with type 2 diabetes. Materials and Methods The primary analysis was a Bucher aITC of the change from baseline at week 40 in HbA1c (%) and body weight (kg). Aggregate data from the SURPASS‐2 study that met the HbA1c inclusion criterion of the SUSTAIN FORTE study and from SUSTAIN FORTE metformin‐only treated patients were used for primary analysis. Results The SURPASS‐2 refined population comprised 238/245/240 and 240 participants for tirzepatide 5/10/15 mg and semaglutide 1 mg, respectively. The SUSTAIN FORTE metformin‐only population comprised 222 and 227 participants for semaglutide 1 and 2 mg, respectively. In this aITC, tirzepatide 10 and 15 mg significantly reduced HbA1c versus semaglutide 2 mg with an estimated treatment difference (ETD) of −0.36% (95% confidence interval [CI] −0.63, −0.09) and −0.4% (95% CI −0.67, −0.13), respectively. Tirzepatide 10 and 15 mg significantly reduced body weight versus semaglutide 2 mg with an ETD of −3.15 kg (95% CI −4.84, −1.46) and −5.15 kg (95% CI −6.85, −3.45), respectively. There were no significant differences between tirzepatide 5 mg and semaglutide 2 mg on change from baseline in HbA1c and body weight. Conclusions In this aITC, HbA1c and weight reductions were significantly greater for tirzepatide 10 and 15 mg versus semaglutide 2 mg and were similar for tirzepatide 5 mg versus semaglutide 2 mg. These findings provide comparative effectiveness insights in the absence of a head‐to‐head clinical trial.

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1

“…Larger, more complex networks of randomized controlled trials are usually analyzed using Bayesian methodology [6-8, 16, 18], whereas the structure of our network allowed the use of the simpler Bucher analysis. This method has been widely used in various therapeutic areas and has not been shown to generate generally consistent results in similarly structured networks [21][22][23][24][25]. All the trials included in the analysis were designed to demonstrate anticipated equivalence between the treatment regimens.…”

Glucagon-like peptide 1 receptor agonists in the treatment of type II diabetes

“…Studies have proven that semaglutide can be taken orally. Both once-weekly subcutaneous inject semaglutide and once-weekly oral semaglutide significantly reduced HbA 1c compared to placebo [15].In 2022, the GIP and GLP-1 dual agonist tirzepatide was approved for marketing by the FDA which have higher efficiency than semaglutide [16]. and bringing diabetes treatment into a new era of the double receptor antagonist.…”

Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective

“…However, an adjusted indirect treatment comparison using data from SURPASS-2 and SUSTAIN FORTE, leveraged the semaglutide 1 mg comparator to assess the treatment effect of semaglutide 2 mg and tirzepatide 5, 10 and 15 mg on an aggregate data population. 115 In this adjusted indirect treatment comparison, tirzepatide 10 and 15 mg significantly reduced HbA1c and body weight versus semaglutide 2 mg whereas there were no differences between tirzepatide 5 mg and semaglutide 2 mg. The magnitude of these differences were also clinically meaningful, with an estimated treatment difference for HbA1c reduction of 0.4% and body weight reduction of 3-5 kg for tirzepatide 10 and 15 mg compared with semaglutide 2 mg.…”